Richard Newlitter
Analyst, Truist Securities
Replay available
Carlsmed, Inc. (NASDAQ: CARL) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Analyst, Truist Securities
Investor Relations
Chief Financial Officer
Chief Executive Officer & Chairman
Analyst, Piper Sandler
And welcome to the Carl Smith Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. I would now like to turn the conference over to your first speaker today, Caroline Corner, Investor Relations. Please go ahead, Caroline. Thank you, Operator. Welcome to Carl Smith's Third Quarter 2025 Earnings Call. Joining me on today's call are Mike Cordonier, Chief Executive Officer and Chairman, and Leo Greenstein, Chief Financial Officer. Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Security Litigation Reform Act 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the market in which Carls Med operates, trends, expectations, and demands for Carls Med's products, and Carls Med's expected financial performance, and position in the market. Any forward-looking statement provided during this call, including projections for future performance, is based on management expectations as of today. Carlsbad undertakes no obligation to update these statements except as required by applicable law. These statements are neither promises nor guarantees and are subject to known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement. For more detailed information, please review the cautionary notes on the earnings materials accompanying today's presentation, as well as Carls Med's filings with the SEC, particularly the risk fact...